Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment-Reference-Cited by-同舟云学术

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

Published:2023-01-17 Issue:2 Volume:133 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Arrieta Víctor A.^ORCID,Dmello Crismita^ORCID,McGrail Daniel J.^ORCID,Brat Daniel J.,Lee-Chang Catalina^ORCID,Heimberger Amy B.^ORCID,Chand Dhan,Stupp Roger^ORCID,Sonabend Adam M.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/163447/files/pdf

Reference96 articles.

1. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

2. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial;Omuro;Neuro Oncol

3. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

4. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

5. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indoleamine 2,3-dioxygenase-1 involves in CD8+T cell exhaustion in glioblastoma via regulating tryptophan levels;International Immunopharmacology;2024-12

2. GBM immunotherapy: Exploring molecular and clinical frontiers;Life Sciences;2024-11

3. Pickering emulsion-guided monomeric delivery of monophosphoryl lipid A for enhanced vaccination;Journal of Controlled Release;2024-10

4. Advances in the treatment of IDH-mutant gliomas;Current Opinion in Neurology;2024-09-12

5. Open‐Source Throttling of CD8⁺ T Cells in Brain with Low‐Intensity Focused Ultrasound‐Guided Sequential Delivery of CXCL10, IL‐2, and aPD‐L1 for Glioblastoma Immunotherapy;Advanced Materials;2024-09-12